Tıp Fakültesi / Faculty of Medicine

Permanent URI for this collectionhttps://hdl.handle.net/11727/1403

Browse

Filters

2017 - 201952020 - 20215

Settings

Author: search.filters.author.Aytan, Pelinsearch.filters.applied.f.rights: search.filters.rights.info:eu-repo/semantics/closedAccess

Search Results

Now showing 1 - 10 of 10
  • No Thumbnail Available
    Item
    Optimization of Minimal Residual Disease Detection by Multi-Color Flow Cytometry in Multiple Myeloma: 8 Colors and Beyond
    (2017) Kozanoglu, Ilknur; Buyukkurt, Nurhilal; Unver, Gulsah; Aytan, Pelin; Yeral, Mahmut; Boga, Can; Ozdogu, Hakan; 0000-0002-9580-628X; 0000-0002-5268-1210; 0000-0002-2553-7715; 0000-0002-0895-4787; 0000-0002-8902-1283; 0000-0002-9680-1958; ABC-4148-2020; AAE-1241-2021; AAE-3833-2019; AAE-1457-2021; AAD-5542-2021; AAD-6222-2021
  • No Thumbnail Available
    Item
    Quantum Cell Expansion System: Safe and Rapid Expansion
    (2017) Kozanoglu, Ilknur; Maytalman, Erkan; Gereklioglu, Cigdem; Yeral, Mahmut; Buyukkurt, Nurhilal; Aytan, Pelin; Boga, Can; Ozdogu, Hakan; 0000-0002-5268-1210; 0000-0001-5284-7439; 0000-0002-9580-628X; 0000-0002-0895-4787; 0000-0002-2553-7715; 0000-0002-9680-1958; 0000-0002-8902-1283; 28803897; AAE-1241-2021; F-6265-2019; ABC-4148-2020; AAE-1457-2021; AAE-3833-2019; AAD-5542-2021
  • No Thumbnail Available
    Item
    Corticosteroid-Induced Vaso-Occlusive Events May Be Prevented by Lowering Hemoglobin S Levels in Adults With Sickle Cell Disease
    (2017) Yeral, Mahmut; Boga, Can; Aytan, Pelin; Ozdogu, Hakan; 0000-0002-9580-628X; 0000-0002-2553-7715; 0000-0002-8902-1283; 28988593; ABC-4148-2020; AAD-6222-2021; AAE-3833-2019; AAD-5542-2021
  • No Thumbnail Available
    Item
    Granulocyte-Colony Stimulating Factor Administration Among Hemoglobin S Trait Donors: A Single Center Experience from The Eastern Mediterranean Region
    (2018) Gereklioglu, Cigdem; Asma, Suheyl; Korur, Asli; Tepebasi, Songul; Aytan, Pelin; Yeral, Mahmut; Kozanoglu, Ilknur; Boga, Can; Ozdogu, Hakan; https://orcid.org/0000-0001-5335-7976; https://orcid.org/0000-0002-5086-5593; https://orcid.org/0000-0002-2553-7715; https://orcid.org/0000-0002-9580-628X; https://orcid.org/0000-0002-5268-1210; https://orcid.org/0000-0002-8902-1283; 28699692; AAI-7831-2021; AAD-5616-2021; AAE-3833-2019; ABC-4148-2020; AAE-1241-2021; AAD-6222-2021; AAD-5542-2021
    Background and Objective: Assessment of Hemoglobin S trait donors has gained importance together with the increased allogeneic peripheral stem cell transplant activity for sickle cell disease in the regions where the disease is prevalent. Outcomes of Granulocyte-Colony Stimulating Factor (G-CSF) administration are obscure for hemoglobin S trait donors. This study aims at investigating the incidence of hemoglobin S carrier status and outcomes of G-CSF administration among donors who live in Eastern Mediterranean region. Material and Method: The cross-sectional, single-center cohort study was performed with 147 donors between January 2013 and March 2017. Prevalence of hemoglobin S trait was estimated and subjects with or without Hemogobin S trait were compared with regard to stem cell characteristics, early and late clinical outcomes after G-CSF administration. Results: Eleven out of 147 donors (7.48%) were found as hemoglobin S trait. G-CSF administration was successfully completed and yielded good harvesting results in hemoglobin S trait donors. No statistically significant difference was found between groups with regard to early and late side effects, stem cell characteristics. Blood pressures and QTc values were within normal ranges in both groups. Groups were similar with regard to CD34 values. Conclusion: 1G-CSF seems safe in hemoglobin S trait donors. Their being eligible as donors would increase the chance of the patients for allogeneic stem cell transplantation in high prevalence regions. Further studies are required to reveal the safety profile of G-SCF in hemoglobin S carriers in different regions.
  • No Thumbnail Available
    Item
    Survival Outcomes of Young Multiple Myeloma Patients: A Single Center Experience
    (2018) Aytan, Pelin; Yeral, Mahmut; Gereklioglu, Cigdem; Korur, Asli; Tanrikulu, Funda; Solmaz, Soner; Buyukkurt, Nurhilal; Kasar, Mutlu; Asma, Suheyl; Boga, Can; Kozanoglu, Ilknur; Ozdogu, Hakan; AAL-3906-2021; 0000-0002-2553-7715; 0000-0002-9580-628X; 0000-0002-5086-5593; 0000-0002-0895-4787; 0000-0003-3856-7005; 0000-0002-9680-1958; 0000-0002-5268-1210; 0000-0002-8902-1283; AAE-3833-2019; ABC-4148-2020; AAD-5616-2021; AAE-1457-2021; AAD-6222-2021; AAE-1241-2021; AAD-5542-2021
  • No Thumbnail Available
    Item
    Factors Associated With Overall Survival in Acute Myeloid Leukemia Patients Before and After Hematopoietic Stem Cell Transplant
    (2021) Aytan, Pelin; Yeral, Mahmut; Korur, Asli; Gereklioglu, Cigdem; Kasar, Mutlu; Buyukkurt, Nur Hilal; Asma, Suheyl; Kazanoglu, Ilknur; Ozdogdu, Hakan; Boga, Can; 0000-0002-5086-5593; 0000-0001-5335-7976; 0000-0002-5268-1210; 0000-0002-9580-628X; 31424361; AAD-5616-2021; AAI-7831-2021; AAE-1241-2021
    Objectives: Our aim was to identify factors associated with overall survival and the efficacy of postrelapse treatment protocols and to determine whether pretransplant consolidation therapy and minimal residual disease status pose a survival benefit. Materials and Methods: Patients with acute myeloid leukemia who underwent stem cell transplant between 2007 and 2018 were enrolled retrospectively. The effects of pretransplant cytogenetic and minimal residual disease status, pretransplant consolidation therapies, development of graft-versus-host disease, postrelapse treatment protocols, and type of conditioning regimens on overall survival were analyzed. Results: In 76 study patients, the cumulative overall 1- and 5-year relapse probabilities were 67.8% and 58.7%, respectively. Overall survival rates at 3 and 5 years in patients with and without relapse were 23.5% and 0% and 95.9% and 91.1% (P<.001), respectively. Although mean postrelapse overall survival was better with intensive salvage plus donor lymphocyte infusion, no significant differences were shown versus other therapies (intensive salvage, nonintensive salvage, intensive salvage or nonintensive salvage plus donor lymphocyte infusion, or supportive therapy). Twenty-three patients (30.3%) died during the study period with a median survival of 9.6 months. Patients with favorable, intermediate, and unfavorable cytogenetic status showed overall survival of 46.6 +/- 10.4, 54.6 +/- 4.4, and 36.9 +/- 5.9 months (P=.807). Patients with and without minimal residual disease and patients who received or did not receive consolidation therapy had similar overall survival. Relapse was an independent predictor of overall survival (increased mortality risk of 26.22). Patients who developed graft-versus-host disease showed decreased relapse. Conclusions: Relapse is the most important predictor of overall survival and is associated with poor prognosis. Pretransplant minimal residual status and cytogenetic status showed no effect on relapse rates and overall survival, and consolidation therapy did not improve outcomes.
  • No Thumbnail Available
    Item
    Excellent outcomes of allogeneic transplantation from peripheral blood of HLA-matched related donors for adult sickle cell disease with ATLG and posttransplant cyclophosphamide-containing regimen: an update work
    (2020) Ozdogu, Hakan; Boga, Can; Yeral, Mahmut; Kozaoglu, Ilknur; Gereklioglu, Cigdem; Aytan, Pelin; Kasar, Mutlu; Asma, Suheyl; Buyukkurt, Nurhilal; Korur, Asli; Sariturk, Cagla; 0000-0002-0895-4787; 0000-0001-5335-7976; 0000-0002-5086-5593; 0000-0003-3856-7005; 0000-0002-8902-1283; 0000-0002-5268-1210; 0000-0002-9580-628X; 0000-0002-9680-1958; 31992850; AAL-6544-2020; AAE-1457-2021; AAS-7129-2021; ABC-4148-2020; AAI-7831-2021; AAD-5616-2021; AAL-3906-2021; AAD-5542-2021; AAE-1241-2021; AAD-6222-2021
  • No Thumbnail Available
    Item
    Significance of Lymphocyte Count, Monocyte Count, and Lymphocyte-To-Monocyte Ratio in Predicting Molecular Response in Patients with Chronic Myeloid Leukemia: a Single-Centre Experience
    (2020) Pepedil-Tanrikulu, Funda; Buyukkurt, Nurhilal; Korur, Asli; Sariturk, Cagla; Aytan, Pelin; Boga, Can; Ozdogu, Hakan; Kozanoglu, Ilknur; 0000-0002-5268-1210; 0000-0002-0895-4787; 0000-0002-8902-1283; 0000-0002-5086-5593; 0000-0002-9680-1958; 32162884; AAE-1241-2021; AAD-6222-2021; AAE-1457-2021; AAD-5542-2021; AAD-5616-2021
    Background: Chronic myeloid leukemia (CML) is a disease resulting from BCR-ABL gene fusion. It is possible to monitor treatment by molecular testing for BCR-ABL. The lymphocyte-to-monocyte ratio (LMR) is a commonly used marker associated with prognosis in various neoplasms. This study was performed to evaluate the relevance of absolute lymphocyte count (ALC), absolute monocyte count (AMC), and LMR in predicting molecular response status in patients with chronic phase CML. Methods: Samples submitted to our hematology laboratory for BCR-ABL testing between April 2012 and October 2018 were retrospectively reviewed. Concurrent hemogram testing together with the results of quantitative reverse transcriptase-polymerase chain reaction were noted. Data were grouped according to molecular response status and the ALC, AMC, and LMR were compared among patient groups. Results: A total of 224 samples from 95 patients were included in the study. Analysis revealed differences between groups when newly diagnosed patients were compared with patients undergoing treatment, regardless of response status. However, analyzing the groups according to molecular response status failed to reveal differences in ALC, AMC, or LMR. Conclusions: ALC, AMC, and LMR are not potential biomarkers for predicting molecular response status in patients with chronic phase CML.
  • No Thumbnail Available
    Item
    The Impact of the Ferric Carboxymaltose on Hemoglobin and Ferritin Levels
    (2020) Korur, Asli; Gereklioglu, Cigdem; Asma, Suheyl; Aytan, Pelin; Tanrikulu, Funda P.; Solmaz, Soner; Kasar, Mutlu; Buyukkurt, Nurhilal; Yeral, Mahmut; Boga, Can; Ozdogu, Hakan; 0000-0003-3856-7005; 0000-0002-8902-1283; 0000-0002-5086-5593; 0000-0002-0895-4787; 0000-0001-5335-7976; 0000-0002-9580-628X; 0000-0002-9680-1958; 32776750; AAD-6222-2021; AAL-3906-2021; AAD-5542-2021; AAD-5616-2021; AAE-1457-2021; ABC-4148-2020; AAI-7831-2021
    Background: Anemia is a frequent disorder worldwide. Iron deficiency anemia (IDA) is the most common form of anemia. Although oral iron is the first choice for treatment, the efficacy of oral iron preparations may be limited. Ferric carboxymaltose (FCM) is a novel parenteral iron preparation which can rapidly replenish iron stores. The aim of the present study is to investigate the impact of FCM dose on hemoglobin (Hb) and ferritin levels and the frequency of hypersensitivity reactions. Methods: This study was conducted with 765 IDA patients between September 1, 2016 and September 1, 2018. Hemoglobin (Hb), serum ferritin, transferrin saturation values were examined at the time of diagnosis, Hb and ferritin values at first month. Results: Post-treatment Hb and ferritin levels significantly increased. The mean Hb level alteration was 2.43 +/- 1.2 g/dL, the median ferritin level alteration was 157.3 ng/mL. The mean Hb level was lower and the mean change in Hb level was higher in higher doses. Allergic reactions were more frequent in higher doses. Conclusions: Ferric carboxymaltose is a novel treatment option with a low risk of hypersensitivity reactions and well tolerated even in high doses.
  • No Thumbnail Available
    Item
    A Comparison of the BEAM and MITO/MEL Conditioning Regimens for Autologous Hematopoietic Stem Cell Transplantation in Hodgkin Lymphoma: An Analysis of Efficiency and Treatment-Related Toxicity
    (2020) Yeral, Mahmut; Aytan, Pelin; Gungor, Burcu; Boga, Can; Unal, Ali; Koc, Yener; Kaynar, Leylagul; Buyukkurt, Nurhilal; Eser, Bulent; Ozdogu, Hakan; 0000-0002-8902-1283; 0000-0002-0895-4787; 0000-0002-9680-1958; 0000-0002-9580-628X; 32605899; AAD-5542-2021; AAE-1457-2021; AAD-6222-2021
    In this multicenter retrospective study, we compared the efficacy and toxicity of BEAM (BCNU, etoposide, cytarabine, and melphalan) and MITO/MEL (mitoxantrone, melphalan) preparation regimens. The 3-year expected overall survival for the MIT/MEL and BEAM were 86.1% and 91.3%, respectively. The MITO/MEL seems to be as effective as the BEAM but has better tolerability in terms of pulmonary toxicity and may be used as an alternative option. Background: Approximately half of patients with relapsed chemosensitive disease achieve robust responses with BEAM (BCNU, etoposide, cytarabine, and melphalan) and autologous stem cell rescue. The scarcity of comparative studies further limits alternative treatment protocols, such as the MITO/MEL (mitoxantrone, melphalan) protocol. Patients and Methods: In this retrospective multicenter study, we compared the BEAM and MITO/MEL regimens used before autologous hematopoietic stem cell transplantation (ASCT) in terms of efficacy and side effects in patients with Hodgkin lymphoma. Data met international accreditation rules. Before ASCT, 108 patients received the MITO/MEL, and 34 patients received the BEAM. Results: The median follow-up time was 36 months in the MITO/MEL group (range, 3-178) and 23 months in the BEAM group (range, 4-99). After ASCT, the 3-year expected overall survival and disease-free survival rates were 86.1% and 86.1% for the MITO/MEL group and 91.3% and 76.5% for the BEAM group, respectively. Although 50% of patients developed febrile neutropenia attacks in the MITO/MEL group, this rate was 91.1% in the BEAM group. The grade II and higher rates of hepatic, renal, gastrointestinal, and cardiac toxicities were similar in both groups. However, the rate of pulmonary toxicity was determined to be 1.9% in the MITO/MEL group and 29.4% in the BEAM group (P < .001). Conclusion: The MITO/MEL conditioning regimen seems to be as effective as the BEAM regimen but has better tolerability in terms of pulmonary toxicity and may be used as an alternative option if necessary, depending on the comorbidity status of the patient.